Government to back Ilyang’s new influenza antiviral drug development

Published: 2013-04-09 06:57:00

Updated: 2013-04-09 06:57:00

The Transgovernmental Enterprise for Pandemic Influenza in Korea (TEPIK), which was established by the Ministry of Health and Welfare in November 2010, has recently unveiled its plan to sponsor and support Ilyang Pharm’s novel anti-influenza virus drug co-developed by Hallym University.

Under...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK